# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hubert H. Humphrey (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML022-SYN-TD
- Date: 1977-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandvold, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Wants his follow-up after bladder removal and his urostomy managed close to home and work **S**
- Bothered by appliance leaks and sore skin around the stoma, which interrupt his long working days **S**

## Your goals

- Leak-free urostomy appliance with healthy peristomal skin. Target: 1977-04-07. Recorded outcome: Appliance refitted with a convex wafer at the consultation; no leaks in the two months after the refit and skin healed. **S**
- Stable kidney function (creatinine within 0.3 mg/dL of the post-operative baseline) and bicarbonate 22 mmol/L or more. Target: 1977-07-07. Recorded outcome: Creatinine 1.10 mg/dL; bicarbonate 24 mmol/L on sodium bicarbonate. **S**
- Regain stamina after surgery: walk 30 minutes a day and regain weight. Target: 1977-04-07. Recorded outcome: Walking 30 minutes most days; weight up 1.1 kg since the first visit. **S**
- Written survivorship surveillance schedule in place, shared between urology and primary care. Target: 1977-07-07. Recorded outcome: Schedule given; CT due at one year after surgery. **S**

## What we agreed to do

- Urology consultation to share survivorship surveillance after radical cystectomy, review the stoma, and set the metabolic monitoring plan. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026) **S**
- Cancer surveillance after cystectomy for pT2a N0 disease: CT or MRI of the chest, abdomen, and pelvis every 6 to 12 months for 2 to 3 years, then yearly; no adjuvant therapy. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Kidney and metabolic monitoring after an ileal conduit: chemistry with creatinine, chloride, and bicarbonate every 3 to 6 months in the first year, then yearly; upper-tract imaging every 6 months to year 3; vitamin B12 yearly; alkali for bicarbonate below 22 mmol/L. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Stoma care with the wound, ostomy, and continence nurse: appliance fitting, peristomal skin care, and parastomal hernia checks. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Urine infection plan with a conduit: no routine urine cultures or treatment of bacteriuria without symptoms; for fever, flank pain, or rigors, a culture taken by catheter from the stoma and prompt treatment; about 2 liters of fluid a day. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); Trautner BW, et al. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections (2025) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**

## Follow-up

- 1977-01-06: First visit to establish shared care three months after radical cystoprostatectomy with an ileal conduit for bladder cancer **S**
- 1977-02-03: Four-week follow-up with urology consultation: surveillance plan, stoma and peristomal skin, and metabolic monitoring **S**
- 1977-04-07: Six-month post-cystectomy follow-up: kidney function, acid-base, upper-tract ultrasound, and review after a kidney infection **S**
- 1977-06-02: Subsequent annual wellness visit **S**
- 1977-07-07: Nine-month post-cystectomy follow-up: acid-base on bicarbonate, stoma review, and the surveillance schedule **S**

This teaching document does not replace care from a qualified clinician.
